Maria Berkman

Maria Berkman, MD, MBA, is a Director, and Head of the MedTech practice at Broadview Ventures. Maria shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement. Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group (now Monitor Deloitte), where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercialization strategy and competitive strategic planning for a broad range of BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery, and earned an MBA from the Anderson School of Management at UCLA. Maria serves on the boards of 480 Biomedical, Adient, BioKier, Cardialen, FineHeart, Vascular Graft Solutions, Vectorious, and Zumbro Discovery, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR). In addition to her role at Broadview Ventures, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.